MXPA00012842A - Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih. - Google Patents

Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.

Info

Publication number
MXPA00012842A
MXPA00012842A MXPA00012842A MXPA00012842A MXPA00012842A MX PA00012842 A MXPA00012842 A MX PA00012842A MX PA00012842 A MXPA00012842 A MX PA00012842A MX PA00012842 A MXPA00012842 A MX PA00012842A MX PA00012842 A MXPA00012842 A MX PA00012842A
Authority
MX
Mexico
Prior art keywords
hiv
mutation
dideoxyuridine
azido
combination
Prior art date
Application number
MXPA00012842A
Other languages
English (en)
Inventor
Raymond Schinazi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MXPA00012842A publication Critical patent/MXPA00012842A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se ha descubierto que la 3Æ-azido-2Æ,3Æ-didesoxiuridina (CS-87) induce una mutacion transiente del VIH-1 en el 70.. Codon (K a R, por ejemplo, lisina a arginina) de la region de transcriptasa inversa del virus. Basados en este descubrimiento, se proporcionan un metodo y composicion para el tratamiento del VIH, el cual incluye la administracion de CS-87 o su sal o prodroga farmaceuticamente aceptable a un humano que necesita la terapia en combinacion o alternacion con una droga que induce la mutacion del VIH-1 en una ubicacion diferente al 70.. Codon de la region de transcriptasa inversa. La presente invencion puede ser practicada haciendo referencia a los patrones conocidos de mutacion publicados para las drogas contra el VIH, o determinando el patron de mutacion para una nueva droga.
MXPA00012842A 1998-06-24 1999-06-24 Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih. MXPA00012842A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9055298P 1998-06-24 1998-06-24
US13212699P 1999-04-30 1999-04-30
PCT/US1999/014329 WO1999066936A1 (en) 1998-06-24 1999-06-24 Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Publications (1)

Publication Number Publication Date
MXPA00012842A true MXPA00012842A (es) 2004-06-22

Family

ID=26782403

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00012842A MXPA00012842A (es) 1998-06-24 1999-06-24 Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.

Country Status (8)

Country Link
US (2) US6194391B1 (es)
EP (1) EP1089741A1 (es)
JP (2) JP2002518452A (es)
AU (1) AU4716299A (es)
BR (1) BR9911457A (es)
CA (1) CA2335617C (es)
MX (1) MXPA00012842A (es)
WO (1) WO1999066936A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
AU4716299A (en) * 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
AU5475799A (en) * 1998-08-10 2000-03-06 Centre National De La Recherche Scientifique Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis
GB9820420D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
CA2360039C (en) * 1999-01-22 2009-11-24 Emory University Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
EP1731155A3 (en) * 1999-01-22 2007-02-21 Emory University Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections
US7115584B2 (en) 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
MXPA02009534A (es) 2000-03-30 2003-05-14 Squibb Bristol Myers Co Granulos de liberacion sostenida que contienen estavudina.
CA2405912A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
AU2002359518A1 (en) * 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
PT1572095E (pt) * 2002-09-13 2015-10-13 Novartis Ag Β-l-2'-desoxinucleósidos para tratamento de estirpes resistentes de vhb
ATE442375T1 (de) * 2002-10-31 2009-09-15 Metabasis Therapeutics Inc Cytarabin-monophosphate prodrugs
NZ540728A (en) * 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
KR20070114806A (ko) * 2005-03-07 2007-12-04 어드벤트륵스 파마슈티칼스, 인크. 바이러스 감염 치료에의 티오포스포노포름산 및 ｎｒｔｉ의용도
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
WO2011066260A2 (en) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012267786B2 (en) 2011-06-10 2017-08-03 Oregon Health & Science University CMV glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN106061984A (zh) 2014-02-13 2016-10-26 配体药物公司 前药化合物及其用途
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099010A (en) 1983-01-17 1992-03-24 Research Corporation Intermediates in the preparation of 3'-amino-2',3'-dideoxycytidine and the pharmacologically acceptable salts thereof
GB2181128A (en) 1985-09-17 1987-04-15 Wellcome Found 3'-azidonucleosides
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5084445A (en) * 1986-05-01 1992-01-28 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine
US5110987A (en) 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
DE3840044A1 (de) 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
NZ232912A (en) * 1989-03-17 1992-06-25 Oncogen Ltd Lp Synergistic composition of nucleoside derivatives for inhibiting hiv
DE3916072A1 (de) 1989-05-17 1990-11-22 Thera Ges Fuer Patente Ceramidderivate und ihre verwendung als inhibitoren der sphingolipidsynthese
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ATE131730T1 (de) * 1991-05-16 1996-01-15 Glaxo Group Ltd Nukleosidanalogen enthaltende antiviren- zubereitungen
US5232837A (en) 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5317009A (en) * 1991-08-26 1994-05-31 New York University Anti-HIV proteins GAP 31, DAP 30 and DAP 32 and therapeutic uses thereof
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DE69317428T2 (de) * 1992-08-19 1998-07-02 Schering Corp Methode zur inhibition von hiv-replikation mittels il-4
WO1994017097A1 (en) * 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
ATE196509T1 (de) 1993-05-06 2000-10-15 Dsm Nv Enzymatische synthese von ceramiden und hybrid- ceramiden
JPH0797324A (ja) * 1993-06-03 1995-04-11 Mitsubishi Chem Corp 抗ウイルス剤
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5616578A (en) * 1993-08-26 1997-04-01 The Dupont Merck Pharmaceutical Company Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor
ES2117304T3 (es) 1993-10-18 1998-08-01 Virginia Tech Intell Prop Sintesis de esfingosinas.
US5637589A (en) * 1993-10-29 1997-06-10 University Of North Carolina At Chapel Hill Suksdorfin, analogs, compositions thereof, and methods for making and using thereof
EP0726960B1 (en) 1993-11-03 2003-02-19 Cosmoferm B.V. Microbial strains producing sphingolipid bases
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US5430169A (en) 1994-02-14 1995-07-04 The United States Of America Represented By The Department Of Health And Human Services Method for preparation of sphingoid bases
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
GB2292146A (en) * 1994-08-11 1996-02-14 Merck & Co Inc HIV protease inhibitors useful for the treatment of AIDS
US5635536A (en) 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5811390A (en) * 1995-08-22 1998-09-22 Metatron, Inc. Use of beta HCG for the control of retroviral infection
US5705522A (en) * 1995-09-15 1998-01-06 Compagnie De Developpement Aguettant S.A. Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
DE19602108A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
AU719691B2 (en) * 1996-01-26 2000-05-18 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
JPH09323932A (ja) * 1996-01-31 1997-12-16 Sankyo Co Ltd エイズ治療剤又は予防剤
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
BR9708592A (pt) * 1996-04-04 1999-08-03 Shionogi & Co Composição anti-hiv compreendo derivados de imida-zol
JP2000509392A (ja) * 1996-05-02 2000-07-25 メルク エンド カンパニー インコーポレーテッド Ａｉｄｓの治療に有効なｈｉｖプロテアーゼ阻害剤
PL330791A1 (en) * 1996-06-25 1999-06-07 Glaxo Group Ltd Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections
WO1998004569A1 (en) * 1996-07-26 1998-02-05 Gilead Sciences, Inc. Nucleotide analogs
AU722489B2 (en) * 1996-11-08 2000-08-03 Du Pont Pharmaceuticals Company (4r,5s,6s,7r)-hexahydro-1- {5-(3-aminoinazole)methyl} -3-butyl-5,6-dihydr oxy-4,7-bis {phaenylmethyl} -2h-1,3-diazepin-2-one, its preparation and its use as HIV protease inhibitor
US5849793A (en) * 1997-08-15 1998-12-15 The Picower Institute For Medical Research HIV matrix protein tyrosine position 29 pocket binders
AU4716299A (en) * 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Also Published As

Publication number Publication date
WO1999066936A9 (en) 2000-04-06
AU4716299A (en) 2000-01-10
WO1999066936A1 (en) 1999-12-29
CA2335617A1 (en) 1999-12-29
US20010009906A1 (en) 2001-07-26
US6602664B2 (en) 2003-08-05
JP2010280724A (ja) 2010-12-16
JP2002518452A (ja) 2002-06-25
EP1089741A1 (en) 2001-04-11
CA2335617C (en) 2009-12-15
BR9911457A (pt) 2001-12-11
US6194391B1 (en) 2001-02-27

Similar Documents

Publication Publication Date Title
MXPA00012842A (es) Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
BG104984A (en) 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
JP2002528502A5 (es)
BG105173A (en) Novel salt form of pantoprazole
KR910700045A (ko) Hiv 감염 관련 질병의 치료
EA200000176A1 (ru) Применение физиологически приемлемых соединений, солей и комплексов ванадия
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
DK416089D0 (da) Heparinfragmenter og -fraktioner med anti-hiv virkning
EP0484112A3 (en) Use of lithium in the treatment or prophylaxis of molluscum contagiosum
BR0007627A (pt) Mutações de hiv-1 selecionadas por beta-2', 3' -didehidro-2', 3' -didesóxi-5-fluorocitidina
KR910018393A (ko) 항바이러스제로서의 비대칭 2-(포스포노메톡시)프로필 구아닌
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
HUP0201629A2 (hu) Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
O'Reilly Efficacy of camptothecin in progressive multifocal leucoencephalopathy
EP1731155A3 (en) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections
Hassel Improvement of muscle function in Charcot‐Marie‐Tooth disease by transcutaneous electric nerve stimulation
JPS62265227A (ja) 薬剤性末梢神経障害の予防・治療剤
Hargrave et al. 5, 11-dihydro-6 H-dipyrido (3, 2-B: 2, 3'-E)(1, 4) diazepines and their use in the prevention or treatment of HIV infection
GR1004470B (el) Μεθοδοι συνθεσης συμπλοκων ενωσεων του βαναδιου (ιιι) με τις σουλφυδρυλικες ενωσεις (-sh, θειολες) κυστεινη (h2cys) και n-(μερκαπτοπροπιονυλ)- γλυκινη για την παρασκευη σκευασματων προοριζομενων για τη θεραπεια του σακχαρωδη διαβητη και των κακοηθων νοσηματων στον ανθρωπο
DE60210804D1 (de) Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit
RU2001102089A (ru) Способ лечения дисциркуляторной энцефалопатии
YU9302A (sh) Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa
NO994712L (no) FremgangsmÕte og sammensetninger for behandling av AIDS- tilknyttet Kaposi-sarkom
RU2000106699A (ru) Способ лечения заболеваний методом настройки биоритмов организма

Legal Events

Date Code Title Description
FG Grant or registration